Comparative analysis of the diagnostic significance of heart failure markers in comorbid patients with atrial fibrillation and chronic obstructive pulmonary disease

Objective: to assess the diagnostic significance of atrial and brain natriuretic peptides for the detection of chronic heart failure in comorbid patients with atrial fibrillation and chronic obstructive pulmonary disease. Materials and methods: 120 patients depending on the presence of chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF) and atrial fibrillation (AF) were divided into the following groups: I group (n=28) — patients with COPD without cardiovascular disease (CVD), II group — patients with CHF and COPD without AF (n=30), III group — patients with CHF and AF without COPD (n=33), IV group — patients with CHF, AF and COPD (n=29). Th e concentration of precursors of brain and atrial natriuretic peptides (NUP) (NT-proBNP and MR-proANP) was evaluated. Results: The level of NT-proBNP exceeded the reference values in all patients with CHF (I, II, III groups). In patients with CHF, AF and COPD the highest values of NT-proBNP concentrations were obtained, which were 2.2 times higher in the group of patients with CHF and COPD without AF (p=0.000) and 1.9 times higher in patients with CHF and AF without COPD (p=0.01). Comparative analysis of the MR-proANP level allowed to judge a higher concentration of this indicator in patients with CHF and COPD without COPD in comparison with the level of the marker in the groups of patients with CHF, AF and COPD (p=0.001), CHF and COPD without AF (p=0.000) and COPD without CVD (p=0.000). Conclusions: in patients with AF and COPD, the study of brain NUP NT-proBNP in connection with structural and functional changes of the right ventricle, against the background of existing cardiac arrhythmias and pulmonary pathology is preferable to determine the presence and severity of CHF. The elevated level of MR-proANP is of diagnostic value in patients with AF and CHF without COPD, due to the increased volume load on the Atria due to the presence of AF.

1. Belenkov YuN., Mareev VYu., Ageev FT., Fomin IV., Badin YuV., Polyakov DS. et al. Veritable prevalence of CHF in the European part of Russia (EPOCHA trial, Hospital stage). Journal Serdechnaya Nedostatochnost’. 2011;12(2):63-68. (in Russ).

2. Maisel WH, Stevenson LW. Atrial fi brillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91:2D–8D. doi:10.1016/S0002- 9149(02)03373-8

3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. European Heart Rhythm Association. European Association for Cardio-Th oracic Surgery Guidelines for the management of atrial fi brillation: Th e Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 31(19):2369–2429. doi: 10.12968/bjca.2011.6.5.240

4. Mareyev VYu., Fomin IV., Ageyev FT., Arutyunov GP., Begrambekova YuL., Belenkov YuN. at al. Clinical recommendations. Chronic heart failure (CHF). Journal Serdechnaya Nedostatochnost’. 2017;18(1):3–40. (in Russ). doi: 10.18087/rhfj .2017.1.2346

5. Belenkov YuN., Mareev YuV. How do we diagnose and treat heart failure in clinical practice at the beginning of the XXI century? Th e results of the study IMPROVEMENT HF. Consilium medicum. 2001;3(2):35-39. (in Russ).

6. Kanorsky SG., Borisenko YuV. Chronic heart failure with preserved ejection fraction: eff ective treatment possible? Kardiologia (Cardiology, Russian journal). 2018;58(6):85–89. (in Russ). doi: 10.18087/cardio.2018.6.10154

7. Fedotova IN., Belopolsky AA., Sturov NV. Diagnostic value of NT-proBNP in cardiac patients. Trudnyy patsiyent (Diffi cult patient). 2013;11(7):22-32. (in Russ).

8. Mrikaev DV. Left ventricular diastolic dysfunction in patients with heart failure. Kreativnaya kardiologiya (Creative Cardiology, Russian journal). 2017;11(2):145–158. (in Russ.). doi: 10.24022/1997-3187-2017-11-2-145-158

9. Nagornaya NV., Pshenichnaya EV., Bordyugova YeV. Clinical Value of Brain Natriuretic Peptide Indicator in Patients with Heart Failure. Zdorove rebenka (Journal of child health). 2011; 2(29):115-120. (in Russ).

10. Alieva AM., Nikitin IG., Starodubova AV., Gogova LM., Gromova OI., Baikova IE et al. Diagnostic and prognostic value of natriuretic peptides in cardiac patients. Lechebnoe delo (Medical Care, Russian journal). 2016;3:78-84. (in Russ).

11. Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115:115–130. doi: 10.1161/ CIRCRESAHA.115.301146.

12. Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fi brillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014;18(19):2908-2917.

13. Melnichenko O.V., Nekrasov A.A., Kuznetsov A.N. Factors Associated with the Development of Atrial Fibrillation in Chronic Obstructive Pulmonary Disease. Int J Biomed. 2011;1(2):71-73.

14. Koziolova NA., Nikonova Yu.N., Shilova Ya.E., Agafonov AV., Polyanskaya EA. Description of chronic heart failure against the back-ground of permanent atrial fi brillation. Journal Serdechnaya Nedostatochnost’. 2013;14(1):14-21. (in Russ).

15. Burnashkina ON., Selezneva NM., Kotlyarov AA. Changes in some hemodynamic parameters in obstructive pulmonary disease. Evraziiskii Soyuz Uchenykh (ESU). (Eurasian Union of Scientists). 2015;7(16):28-31. (in Russ).